When planning for the development of a new product, a pharmaceutical manufacturer must determine very early in the process what a product’s anticipated demand will be at the time of launch. Though pharma companies do their best to understand the environment it can be very difficult to predict demand, and the consequences of incorrect forecasts can be very costly in a number of ways.
Biologics, orphan drugs, and precision medicine are on the rise, and that means some big changes for drug development and manufacturing companies. What should pharma companies look for when navigating this new era of small-volume manufacturing?
The most effective way to stop opioid dependence is to eliminate the use of these addictive drugs after surgery altogether. This was the goal of Pacira Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development of non-opioid products for postsurgical pain control, when it developed its injectable suspension.
Monza has established a new state-of-the-art center of excellence for sterile injectables development. All manufacturing services are fully supported with comprehensive in-house analytical and bioanalytical capabilities.